Anti-PS-II IgA antibodies were found in the stools of patients diagnosed with CDI, suggesting that the synthetic hexasaccharide could be used in a glycoconjugate vaccine candidate against CDI. This evidence concerns the gene CD79A and clostridium difficile infection.